Generic COVID-19 Vaccine Sanofi (CoV2 preS dTM monovalent D614 [recombinant]) 5micrograms/0.5ml dose suspension for injection multidose vials
Vaccines and antisera
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Part of the Comirnaty brand family (generic: COVID-19 vaccine)
MHRA licensed products
View all licensed products for COVID-19 vaccine on the MHRA register
COVID-19 Vaccine Sanofi (CoV2 preS dTM monovalent D614 [recombinant]) 5micrograms/0.5ml dose suspension for injection multidose vials
Therapeutically similar medicines
Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Clinical guidelines and formulary information
British National Formulary
COVID-19 vaccine
Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
NICE clinical guidance(10)
Antenatal care (QS22)
Vaccine uptake in the general population (NG218)
Reducing sexually transmitted infections (NG221)
COVID-19 rapid guideline: managing the long-term effects of COVID-19 (NG188)
Molnupiravir for treating COVID-19 (TA1056)
Nirmatrelvir plus ritonavir and tocilizumab for treating COVID-19 (TA878)
Tixagevimab plus cilgavimab for preventing COVID-19 (TA900)
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 (TA971)
Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (TA1114)
Cytokine adsorption devices for treating respiratory failure in people with COVID-19 (MIB217)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
Not available
Mechanism
The antigenic component of VidPrevtyn Beta is a soluble trimeric SARS-CoV-2 recombinant spike protein (B.
Food interactions
None known
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
derived from Sf9 cells of the fall armyworm, Spodoptera frugiperda - combined with GSK's AS03 adjuvant.[A245829][L49696]
In October 2022, VidPrevtyn Beta was approved in the European Union for use as a booster dose in patients who have previously received a COVID-19 vaccine.[L49691]
[L49696]
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
VidPrevtyn Beta
Matched from: COVID-19 vaccine
DrugBank citations
If you use DrugBank data in your research, please cite the following publications: